Dermatologist Highlights Medical Benefits of MelaFind Device in Aiding Melanoma Diagnosis at Most Treatable Stage
January 30 2014 - 7:55AM
Business Wire
“This is the wave of the future for
dermatology.”
MELA Sciences, Inc. (NASDAQ: MELA), developer of
MelaFind®, an FDA approved optical diagnostic
device that assists dermatologists in the diagnosis of melanoma,
hosted a MelaFind® workshop during the 10th Annual
Maui Derm Conference in Hawaii. The conference seeks to increase
physicians’ knowledge of developments in medical and cosmetic
dermatology.
Dr. Monica Scheel, a Board Certified Dermatologist based in
Hawaii, hosted the MelaFind® workshop which reviewed
the clinical use and benefits of the device as well as future
technology development opportunities for the device and its
underlying optical imaging and data analysis technology. Dr. Scheel
had also presented clinical data at MELA Sciences’ Clinical
Advisory meeting at the Winter Clinical Dermatology Conference held
a week earlier.
“Adding MelaFind to my practice has helped mobilize patients
and drive disease awareness; I’m thrilled with this new
technology,” commented Dr. Scheel. “This is the wave of the
future for dermatology, a new way to visualize and analyze
atypical pigmented skin lesions below the skin surface. MelaFind
has helped increase the sensitivity of my biopsies, as well as
helped me prioritize lesions that can be monitored.”
MELA Sciences also displayed four clinical posters at the
well-attended and highly successful Maui Derm conference. The
posters reviewed clinical data from practice and clinical settings
that highlighted how MelaFind has helped dermatologists in the
assessment of clinically ambiguous pigmented skin lesions (moles)
in a variety of patient types including young adults, an area of
growing concern, and those with atypical mole syndrome. The posters
and abstracts are available here.
About MELA Sciences, Inc. www.melasciences.com
MELA Sciences is a medical device company developing dermatology
diagnostics utilizing state-of-the-art optical imaging. The
flagship product is MelaFind®, an FDA, PMA and CE Mark approved,
non-invasive diagnostic tool to aid dermatologists in melanoma
evaluation and diagnosis. MelaFind® uses a variety of visible to
near-infrared light waves to evaluate skin lesions (moles) from the
surface to 2.5 mm beneath the skin. It provides images and data on
the relative disorganization of a lesion's structure that provides
substantial additional perspective to aid melanoma diagnosis. MELA
is also exploring new potential uses for its core imaging
technology and algorithms.
Twitter: MELASciencesIR or MelaFindFacebook: MelaFindStockTwits: MELASciencesIR
MediaMELA Sciences, Inc.Diana Garcia Redruello,
212-518-4226dgarcia@melasciences.comorInvestorsCatalyst
GlobalToni Trigiani, David
Collins212-924-9800mela@catalyst-ir.com
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Apr 2023 to Apr 2024